Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 24, 2007

Gene Logic Tasked with Repositioning Merck Serono Drugs

  • Gene Logic plans to research alternative development paths for several Merck Serono clinical candidates under a drug-repositioning agreement. All the candidates were discontinued or de-prioritized for reasons other than safety, according to the companies.

    Gene Logic will receive success-based milestones and royalties. If Gene Logic identifies a new therapeutic use for any compound, the company has the right to exclusively license the drug so long as Merck Serono opts out of development. Merck Serono then would be entitled to success-based milestone and royalty payments on these licensed candidates.

    Gene Logic has similar repositioning collaborations with Eli Lilly, Lundbeck, Abbott, Organon, Roche, and Pfizer.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »